AP

Researchers: Breast cancer drug could help more patients

Jun 5, 2022, 5:00 AM | Updated: 6:05 am

This undated photo provided by Daiichi Sankyo and AstraZeneca in June 2022 shows a vial and packagi...

This undated photo provided by Daiichi Sankyo and AstraZeneca in June 2022 shows a vial and packaging for their Enhertu, an antibody-chemotherapy drug administered intravenously. (Daiichi Sankyo, AstraZeneca via AP)

(Daiichi Sankyo, AstraZeneca via AP)

For the first time, a drug targeting a protein that drives breast cancer growth has been shown to work against tumors with very low levels of the protein.

It’s not a cure. But this latest gain for targeted cancer therapy could open new treatment possibilities to thousands of patients with advanced breast cancer.

Until now, breast cancers have been categorized as either HER2-positive — the cancer cells have more of the protein than normal — or HER2-negative. Doctors reporting the advance Sunday said it will make “HER2-low” a new category for guiding breast cancer treatment.

About half of patients with late-stage breast cancer formerly categorized as HER2-negative may actually be HER2-low and eligible for the drug.

The drug is Enhertu, an antibody-chemotherapy combo given by IV. It finds and blocks the HER2 protein on cancer cells, while also unloading a powerful cancer-killing chemical inside those cells. It belongs to a relatively new class of drugs called antibody-drug conjugates.

The drug was already approved for HER2-positive breast cancer, and in April the Food and Drug Administration granted it breakthrough status for this new group of patients.

In the new study, the drug lengthened the time patients lived without their cancer progressing and improved survival compared with patients given standard chemotherapy.

The study compared Enhertu to standard chemo in about 500 patients with HER2-low breast cancer that had spread or could not be treated with surgery. The drug stopped the progress of cancer for about 10 months compared with about 5 1/2 months in the group getting regular care. The drug improved survival by about six months (from 17.5 months to 23.9 months).

“It’s a practice-changing study,” said Dr. Sylvia Adams, who directs breast cancer care at NYU Langone Health and enrolled several patients in the study. “It addresses a major unmet need for patients who have metastatic breast cancer.”

Now, it will be important to define the HER2 gray area to make sure the right patients receive the treatment and then to monitor them closely, experts said.

The drug, which costs about $14,000 a month, can have severe complications. Three patients in the study died of a lung disease that’s a known hazard of the drug. Doctors need to make sure patients report breathing problems right away so the drug can be stopped and patients treated with steroids.

The findings were featured Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago and published by the New England Journal of Medicine. Funding for the study came from Tokyo-based Daiichi Sankyo and U.K.-based AstraZeneca, which jointly developed the drug.

Patients take the drug until they can no longer tolerate it.

“A lot of people, including a lot of patients, will not have heard of HER2-low breast cancer before,” said the study’s lead author, Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center in New York.

“We finally have a HER2-targeted drug that for the first time can target that low level of HER2 expression,” Modi said. “This drug actually helps to define HER2-low breast cancer. It makes it, for the first time, a targetable population.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

Former President Donald Trump sits in a courtroom next to his lawyer Todd Blanche before the start ...

Associated Press

Trump hush money trial enters new phase after defense rests without testimony from former president

Donald Trump's hush money trial is now closer to the moment when the jury will begin deciding the former president's fate.

2 days ago

UoA student convicted of first-degree murder after killing professor...

Associated Press

Former Arizona grad student convicted of first-degree murder in 2022 shooting of professor

A former University of Arizona grad student was convicted of first-degree murder after fatally shooting a professor on campus two years ago.

2 days ago

Rudy Giuliani bankruptcy filing defamation lawsuit...

Associated Press

Ex-NYC Mayor Rudy Giuliani, Arizona’s Kelli Ward plead not guilty in fake elector case

Giuliani appeared remotely for the arraignment that was held in a Phoenix courtroom. His trial will take place in October.

2 days ago

President Joe Biden gestures after speaking to graduating students at the Morehouse College commenc...

Associated Press

Biden tells Morehouse graduates that scenes in Gaza from the Israel-Hamas war break his heart, too

Joe Biden on Sunday offered his most direct recognition of U.S. students' anguish over the Israel-Hamas war.

4 days ago

Rudy Giuliani...

Associated Press

Rudy Giuliani is the final defendant served indictment in Arizona fake elector case

Rudy Giuliani has been served an indictment in Arizona's fake elector case for his role in an attempt to overturn the 2020 election.

5 days ago

Follow @ktar923...

Sponsored Content by Collins Comfort Masters

Here's how to be worry-free when your A/C goes out in the middle of summer

PHOENIX -- As Arizona approaches another hot summer, Phoenix residents are likely to spend more time indoors.

Sponsored Articles

...

Condor Airlines

Condor Airlines can get you smoothly from Phoenix to Frankfurt on new A330-900neo airplane

Adventure Awaits! And there's no better way to experience the vacation of your dreams than traveling with Condor Airlines.

...

DESERT INSTITUTE FOR SPINE CARE

Desert Institute for Spine Care is the place for weekend warriors to fix their back pain

Spring has sprung and nothing is better than March in Arizona. The temperatures are perfect and with the beautiful weather, Arizona has become a hotbed for hikers, runners, golfers, pickleball players and all types of weekend warriors.

...

DISC Desert Institute for Spine Care

Sciatica pain is treatable but surgery may be required

Sciatica pain is one of the most common ailments a person can face, and if not taken seriously, it could become one of the most harmful.

Researchers: Breast cancer drug could help more patients